Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR)

Biological Chemistry

Volumn 387, Issue 2, 2006, Pages 217-222

  Beaufort, Nathalie ^a,b   Debela, Mekdes ^b,c   Creutzburg, Sabine ^b   Kellermann, Josef ^c   Bode, Wolfram ^c   Schmitt, Manfred ^b   Pidard, Dominique ^a   Magdolen, Viktor ^b  

^a INSTITUT PASTEUR   (France)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Enamel matrix serine protease 1; Invasion; Metastasis; Prostase; Tumor associated proteolytic system

Indexed keywords

KALLIKREIN; PLASMINOGEN ACTIVATOR; PROSTATE SPECIFIC ANTIGEN; UROKINASE;

AMINO ACID SEQUENCE; CELL SURFACE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KALLIKREINS; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 32344435145     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2006.029     Document Type: Conference Paper

References (32)

1. Almasi, C.E., Høyer-Hansen, G., Christensen, I.J., Danø, K., and Pappot, H. (2005) Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 48, 349-355.
2. Andolfo, A., English, W.R., Resnati, M., Murphy, G., Blasi, F., and Sidenius, N. (2002). Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb. Haemost. 88, 298-306.
3. Beaufort, N., Leduc, D., Rousselle, J.C., Namane, A., Chignard, M., and Pidard, D. (2004a). Plasmin cleaves the juxtamembrane domain and releases truncated species of the urokinase receptor (CD87) from human bronchial epithelial cells. FEBS Lett. 574, 89-94.
4. Beaufort, N., Leduc, D., Rousselle, J.C., Magdolen, V., Luther, T., Namane, A., Chignard, M., and Pidard, D. (2004b). Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J. Immunol. 172, 540-549.
5. Blasi, F. and Carmeliet, P. (2002). uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell. Biol. 3, 932-943.
6. Borgono, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
7. Clements, J.A., Willemsen, N.M., Myers, S.A., and Dong, Y. (2004). The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit. Rev. Clin. Lab. Sci. 41, 265-312.
8. de Bock, C.E. and Wang, Y. (2004). Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 24, 13-39.
9. Dong, Y., Kaushal, A., Bui, L., Chu, S., Fuller, P.J., Nicklin, J., Samaratunga, H., and Clements, J.A. (2001). Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin. Cancer Res. 7, 2363-2371.
10. Fazioli, F., Resnati, M., Sidenius, N., Higashimoto, Y., Appella, E., and Blasi, F. (1997) A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16, 7279-7286.
11. Kugler, M.C., Wei, Y., and Chapman, H.A. (2003). Urokinase receptor and integrin interactions. Curr. Pharm. Des. 9, 1565-1574.
12. Llinas, P., Le Du, M.H., Gårdsvoll, H., Danø, K., Ploug, M., Gilquin, B., Stura, E.A., and Menez, A. (2005). Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 24, 1655-1663.
13. Luther, T., Magdolen, V., Albrecht, S., Kasper, M., Riemer, C., Kessler, H., Graeff, H., Müller, M., and Schmitt, M. (1997). Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am. J. Pathol. 150, 1231-1244.
14. Magdolen, V., Albrecht, S., Kotzsch, M., Haller, C., Bürgle, M., Jacob, U., Großer, M., Kessler, H., Graeff, H., Müller, M., Schmitt, M., and Luther, T. (1998). Immunological and functional analyses of the extracellular domain of human tissue factor. Biol. Chem. 379, 157-165.
15. Magdolen, U., Krol, J., Sato, S., Mueller, M.M., Krüger, A., Sperl, S., Schmitt, M., and Magdolen, V. (2002). Natural inhibitors of tumor-associated proteases. Radiol. Oncol. 36, 131-143.
16. Matsumura, M., Bhatt, A.S., Andress, D., Clegg, N., Takayama, T.K., Craik, C.S., and Nelson, P.S. (2005). Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 62, 1-13.
17. Mizukami, I.F., Faulkner, N.E., Gyetko, M.R., Sitrin, R.G., and Todd, R.F. (1995). Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 86, 203-211.
18. Nelson, P.S., Gan, L., Ferguson, C., Moss, P., Gelinas, R., Hood, L., and Wang, K. (1999). Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc. Natl. Acad. Sci. USA 96, 3114-3119.
19. Obiezu, C.V., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G.M., Fracchioli, S., Rigault de la Longrais, I.A., Arisio, R., and Diamandis, E.P. (2001). Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin. Cancer Res. 7, 2380-2386.
20. Obiezu, C.V., Shan, S.J., Soosaipillai, A., Luo, L.Y., Grass, L., Sotiropoulou, G., Petraki, C.D., Papanastasiou, P.A., Levesque, M.A., and Diamandis, E.P. (2005). Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin. Chem. 51, 1432-1442.
21. Ploug, M. (2003). Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr. Pharm. Des. 9, 1499-528.
22. Preissner, K.T., Kanse, S.M., and May, A.E. (2000). Urokinase receptor: a molecular organizer in cellular communication. Curr. Opin. Cell. Biol. 12, 621-628.
23. Reuning, U., Magdolen, V., Hapke, S., and Schmitt, M. (2003). Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol. Chem. 384, 1119-1131.
24. Sidenius, N., Andolfo, A., Fesce, R., and Blasi, F. (2002). Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J. Biol. Chem. 277, 27982-27990.
25. Sidenius, N., Sier, C.F.M., and Blasi, F. (2000). Shedding and cleavage of the urokinase receptor (uPAR): identification and characterization of uPAR fragments in vitro and in vivo. FEBS Lett. 475, 52-56.
26. Simmer, J.P. and Bartlett, J.D. (2004). Kallikrein 4 is a secreted protein. Cancer Res. 64, 8481-8482.
27. Simmer, J.P., Fukae, M., Tanabe, T., Yamakoshi, Y., Uchida, T., Xue, J., Margolis, H.C., Shimizu, M., DeHart, B.C., Hu, C.C., and Bartlett, J.D. (1998). Purification, characterization, and cloning of enamel matrix serine proteinase 1. J. Dent. Res. 77, 377-386.
28. Sperl, S., Mueller, M.M., Wilhelm, O.G., Schmitt, M., Magdolen, V., and Moroder, L. (2001). The uPA/uPA-receptor system as a target for tumor therapy. Drug News Perspect. 14, 401-411.
29. Takayama, T.K., McMullen, B.A., Nelson, P.S., Matsumura, M., and Fujikawa, K. (2001). Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40, 15341-15348.
30. Xi, Z., Klokk, T.I., Korkmaz, K., Kurys, P., Elbi, C., Risberg, B., Danielsen, H., Loda, M., and Saatcioglu, F. (2004). Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res. 64, 2365-2370.
31. Yousef, G.M. and Diamandis, E.P. (2003). Tissue kallikreins: new players in normal and abnormal cell growth? Thromb. Haemost. 90, 7-16.
32. Yousef, G.M., Obiezu, C.V., Luo, L.Y., Black, M.H., and Diamandis, E.P. (1999). Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res. 59, 4252-4256.